论文部分内容阅读
目的观察阿托伐他汀联合通心络胶囊对急性冠脉综合征(Acute Coronary Syndrome,ACS)患者血浆CRP、IL-8和血脂水平的影响。方法随机将122例ACS患者分为常规对照组和联合治疗组,治疗2个月,比较治疗前后血浆CRP、IL-8和血脂水平变化。结果两组中CRP、IL-8和血脂水平均有不同程度的改变,治疗组下降更明显,与对照组相比,差异有统计学意义(P<0.05)。结论阿托伐他汀联合通心络胶囊治疗ACS患者能够降低其血浆CRP、IL-8和血脂水平,对诊治、预后及稳定粥样斑块等有积极意义。
Objective To observe the effects of atorvastatin combined with Tongxinluo capsule on plasma CRP, IL-8 and serum lipids in patients with acute coronary syndrome (ACS). Methods 122 patients with ACS were randomly divided into routine control group and combination therapy group for 2 months. The changes of plasma CRP, IL-8 and blood lipid levels were compared before and after treatment. Results The levels of CRP, IL-8 and serum lipids in both groups changed to different extents. The decrease in the treatment group was more obvious than that in the control group (P <0.05). Conclusions Atorvastatin combined with Tongxinluo capsule can reduce the level of plasma CRP, IL-8 and blood lipid in patients with ACS, and has positive significance in diagnosis and treatment, prognosis and stable atherosclerotic plaques.